2023 Fiscal Year Final Research Report
Rapid design and preparation of artificial antibodies to inhibit immune checkpoints
| Project/Area Number |
20K06516
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 43020:Structural biochemistry-related
|
|---|
| Research Institution | Institute of Physical and Chemical Research |
|---|
Principal Investigator |
Miyatake Hideyuki 国立研究開発法人理化学研究所, 開拓研究本部, 専任研究員 (50291935)
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 免疫チェックポイント / PD-1/PD-L1 / 人工抗体タンパク質 / 低分子阻害剤 / in-silicoスクリーニング / 抗がん剤 |
|---|
| Outline of Final Research Achievements |
Since the 1980s, cancer has consistently been the leading cause of death in our country, and it is said that one in two citizens will suffer from it in their lifetime. Furthermore, with rapid aging, the number of patients continues to increase. The mainstays of cancer treatment have been surgery, chemotherapy, and radiotherapy, but in recent years, cancer immunotherapy, such as OPDIVO developed by Professor Honjo and others, is becoming the fourth pillar. On the other hand, drugs like OPDIVO are antibody medicines and are problematic due to their high cost, minimally invasive nature, and unexpected immunogenicity.
Therefore, the lead researchers tackled the preparation of artificial antibody proteins and small molecule compounds as alternatives to OPDIVO, using an in-silico/in-cell hybrid selection method. As a result, we succeeded in preparing candidate drugs with immune checkpoint inhibition effects.
|
| Free Research Field |
構造生物化学、計算機構造創薬
|
| Academic Significance and Societal Importance of the Research Achievements |
オプジーボなどのモノクローナル抗体薬は、免疫チェックポイント阻害剤としてだけではなく、抗がん剤や、最近では、アルツハイマーの治療にも使われている。一方、モノクローナル抗体薬は、製造コストが高いため、一般に薬価は高額であり、国の健康医療保険制度に負担をかけている。
そのため、本研究で成功した手法により、モノクローナル抗体医薬品を代替できるようになれば、薬価を抑え、医療コストの抑制につながることが期待できる。これは、国の医療制度の持続可能性を高めることにつながる。
|
